EnteroBiotix

Glasgow-based biopharmaceutical company EnteroBiotix has completed a £19 million ($25 million) financing round. The investment was led by experienced life science investor Thairm Bio and the Scottish National Investment Bank, with participation from new and existing investors.

Summary of transaction details:

• Value: £19 million ($25 million).
• Sector: Pharmaceutical / Biotech.
• Advisor: Not disclosed.
• Key Entities: Target: EnteroBiotix; Lead Investors: Thairm Bio, Scottish National Investment Bank; Key Executive: Dr James McIlroy (CEO).
• Location: Glasgow, Scotland.

Note: EnteroBiotix is a clinical-stage biopharmaceutical company building a leading position in full-spectrum microbiome therapeutics. This £19 million financing will advance its lead candidate, EBX-102-02, into Phase 2b development for Irritable Bowel Syndrome with Constipation (IBS-C). The Phase 2b trial, named 'RISE', is a randomised, double-blind, placebo-controlled interventional trial that will enroll approximately 300 patients across the UK. First patient dosing is anticipated in Q2 2026, with topline efficacy data expected in H2 2027. This funding supports one of the largest trials of a full-spectrum microbiome product ever conducted, demonstrating the growing evidence for the gut microbiome as a tractable target in IBS.